Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 171845, 7 pages
http://dx.doi.org/10.1155/2015/171845
Research Article

Missense Mutations in Exons 18–24 of EGFR in Hepatocellular Carcinoma Tissues

1Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
2Research Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
3Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
4Division of General Surgery, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand

Received 9 June 2015; Revised 19 August 2015; Accepted 24 August 2015

Academic Editor: Atif A. Ahmed

Copyright © 2015 Ravat Panvichian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA: Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. F. Perz, G. L. Armstrong, L. A. Farrington, Y. J. F. Hutin, and B. P. Bell, “The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide,” Journal of Hepatology, vol. 45, no. 4, pp. 529–538, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Parkin, “The global health burden of infection-associated cancers in the year 2002,” International Journal of Cancer, vol. 118, no. 12, pp. 3030–3044, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. A. Wörns, A. Weinmann, M. Schuchmann, and P. R. Galle, “Systemic therapies in hepatocellular carcinoma,” Digestive Diseases, vol. 27, no. 2, pp. 175–188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Liu, Y. Cao, C. Chen et al., “Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5,” Cancer Research, vol. 66, no. 24, pp. 11851–11858, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch, “Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling,” Molecular Cancer Therapeutics, vol. 7, no. 10, pp. 3129–3140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. A.-L. Cheng, Y.-K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. C. L. Arteaga and J. A. Engelman, “ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics,” Cancer Cell, vol. 25, no. 3, pp. 282–303, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Dazzi, P. S. Hasleton, N. Thatcher et al., “Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival,” The British Journal of Cancer, vol. 59, no. 5, pp. 746–749, 1989. View at Publisher · View at Google Scholar · View at Scopus
  11. J. P. Spano, R. Fagard, J.-C. Soria, O. Rixe, D. Khayat, and G. Milano, “Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives,” Annals of Oncology, vol. 16, no. 2, pp. 189–194, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. P. Mak and W. N. William Jr., “Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention,” Oral Oncology, vol. 50, no. 10, pp. 918–923, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Altimari, M. Fiorentino, E. Gabusi et al., “Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours,” Digestive and Liver Disease, vol. 35, no. 5, pp. 332–338, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. A. F. Buckley, L. J. Burgart, V. Sahai, and S. Kakar, “Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma,” American Journal of Clinical Pathology, vol. 129, no. 2, pp. 245–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Ito, T. Takeda, M. Sakon et al., “Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma,” British Journal of Cancer, vol. 84, no. 10, pp. 1377–1383, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Kannangai, F. Sahin, and M. S. Torbenson, “EGFR is phosphorylated at Ty845 in hepatocellular carcinoma,” Modern Pathology, vol. 19, no. 11, pp. 1456–1461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Tsiambas, L. Manaios, C. Papanikolopoulos et al., “Chromogenic in situ hybridization analysis of epidermal growth factor receptor gene/chromosome 7 numerical aberrations in hepatocellular carcinoma based on tissue microarrays,” Pathology & Oncology Research, vol. 15, no. 3, pp. 511–520, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. W. Pao, V. Miller, M. Zakowski et al., “EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 36, pp. 13306–13311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. T. S. Mok, Y.-L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Zhou, Y.-L. Wu, G. Chen et al., “Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study,” The Lancet Oncology, vol. 12, no. 8, pp. 735–742, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. L. V. Sequist, J. C.-H. Yang, N. Yamamoto et al., “Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations,” Journal of Clinical Oncology, vol. 31, no. 27, pp. 3327–3334, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Pao, V. A. Miller, K. A. Politi et al., “Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain,” PLoS Medicine, vol. 2, no. 3, article e73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Kobayashi, T. J. Boggon, T. Dayaram et al., “EGFR mutation and resistance of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 352, no. 8, pp. 786–792, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Ohashi, Y. E. Maruvka, F. Michor, and W. Pao, “Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease,” Journal of Clinical Oncology, vol. 31, no. 8, pp. 1070–1080, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M.-C. Su, H.-C. Lien, and Y.-M. Jeng, “Absence of epidermal growth factor receptor exon 18–21 mutation in hepatocellular carcinoma,” Cancer Letters, vol. 224, no. 1, pp. 117–121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. S.-C. Lee, S.-G. Lim, R. Soo et al., “Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma,” Pharmacogenetics and Genomics, vol. 16, no. 1, pp. 73–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. L. A. DeCicco, J. Kong, and D. P. Ringer, “Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in rat,” Cancer Letters, vol. 111, no. 1-2, pp. 149–156, 1997. View at Publisher · View at Google Scholar · View at Scopus
  30. M. I. G. Ruiz, K. Floor, F. Rijmen, K. Grünberg, J. A. Rodriguez, and G. Giaccone, “EGFR and K-ras mutation analysis in non-small cell lung cancer: comparison of paraffin embedded versus frozen specimens,” Cellular Oncology, vol. 29, no. 3, pp. 257–264, 2007. View at Google Scholar · View at Scopus
  31. T. Takano, Y. Ohe, H. Sakamoto et al., “Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 6829–6837, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Willmore-Payne, J. A. Holden, and L. J. Layfield, “Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck,” Modern Pathology, vol. 19, no. 5, pp. 634–640, 2006. View at Publisher · View at Google Scholar · View at Scopus